Ibrexafungerp is a novel antifungal agent belonging to the triterpenoid class. It is particularly noteworthy for its broad-spectrum activity against a variety of fungal pathogens, including Candida and Aspergillus species. Its unique mechanism of action involves inhibition of the enzyme glucan synthase, crucial for the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall.
